相关实验视频

Updated: May 30, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

针对IKZF1/BCL-2轴作为治疗急性T细胞淋巴细胞白血病的新治疗策略

Juan Li^1,2, Chunmei Ye^1,2, Hui Li¹

¹Department of Hematology, Taixing People's Hospital Affiliated to Yangzhou University, Taixing, China.

Cancer biology & therapy

|January 25, 2025

概括

在T细胞急性淋巴细胞白血病 (T-ALL) 中,IKZF1充当BCL-2抑制剂. 用CX-4945和venetoclax针对CK2-IKZF1通路显示出对T-ALL治疗的希望.

科学领域:

血液瘤学血液瘤学
分子生物学分子生物学
癌症治疗方法癌症治疗方法

背景情况:

急性T细胞淋巴细胞白血病 (T-ALL) 是一种严重的癌症,治疗选择有限.
了解驱动T-ALL的分子机制对于开发新疗法至关重要.

研究的目的:

研究IKZF1在调节T-ALL中的BCL-2表达中的作用.
评估针对T-ALL中的CK2-IKZF1信号轴的治疗潜力.

主要方法:

染色体免疫沉,然后进行测序 (CUT&Tag) 以确定IKZF1结合部位.
在T-ALL细胞系中进行基因表达分析和功能检测.
在体外和体内对CX-4945和venetoclax联合治疗的评估.

主要成果:

IKZF1与BCL-2促进体结合,并作为转录抑制剂,减少BCL-2的表达.
CK2-IKZF1信号轴调节T-ALL细胞中的BCL-2水平.
与CX-4945和venetoclax的联合治疗在T-ALL模型中显示出协同的细胞毒性和亡诱导,在体内有效性优越.

结论:

在T-ALL中,IKZF1介导的BCL-2抑制是T-ALL的关键调节机制.
用CX-4945和venetoclax准CK2-IKZF1轴代表了对T-ALL的有前途的新疗法策略.
联合抑制CK2和BCL-2可提高疗效,并有可能改善T-ALL.患者的治疗结果.

关键词:

在BCL-2中.在 IKZF1 在T细胞急性淋巴细胞白血病.维尼托克莱克斯 (Venetoclax) 是一个

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Published on: July 19, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...